Skip to main content
main-content

05-06-2017 | Image

Figure 2: Key regulatory events for JAK inhibitors in the treatment of RA

Figure 2: Key regulatory events for JAK inhibitors in the treatment of RA


Tofacitinib was approved for use in the USA in June 2012, and for use in Europe in February 2017. Baricitinib was approved in Europe in February 2017, but is not currently approved in the USA [10, 11, 17, 18].

DMARD, disease-modifying antirheumatic drug; EMA, European Medicines Agency; FDA, US Food and Drug Administration; RA, rheumatoid arthritis.